What Every Medical Biller and Financial Officer Should Know about the Amended Michigan No-Fault Insurance Act
10/21/2021 9:00 AM - 1:00 PM
Event Description
WHAT EVERY MEDICAL BILLER AND FINANCIAL OFFICER SHOULD KNOW ABOUT THE AMENDED MICHIGAN NO-FAULT INSURANCE ACT: Information and resources to equip your business to develop and implement strategies to get bills paid and tips on how and when to appeal.
VIRTUAL CONFERENCE
THURSDAY, OCT. 21, 2021
9:00 AM - 1:00 PM
Cost: $200
EVENT CO-HOSTED BY MMBA AND CPAN
Agenda
Overview of PA 21 Changes
PIP “Choice”
New Priority Rules
Changes to Tort Claims/Litigation
New Accreditation Requirement
New Attendant Care Limitation
The New Fee Schedule
Brief Review of the Law:
MCL 500.3157
DIFS’ New Fee Schedule Rules
Relevant DIFS Bulletins
The Spectrum Health Decision
FAQs Answered on Topics Including:
The Use of Codes and Claim Forms
Eligibility for Enhanced Reimbursement
Charge Description Master(s)
The Use of Fair Health Data
Breakout Discussions and Q&A for:
Provider Group I: Larger-scale providers who render treatment that is generally reimbursable under Medicare.
Provider Group II: Smaller-scale providers who render treatment, including, but not limited to, in-home attendant or nursing care or therapy, that is generally not reimbursable by Medicare.
Provider Group III: Including but not limited to, physician offices who render treatment
including office services (Evaluations and Management[E&M], X-rays, & Procedures,
outpatient and inpatient services (E & M & Surgical)
The New Utilization Review Rules and Process Brief Review of the Law:
MCL 500.3157a
DIFS’ New Utilization Review Rules
FAQs Answered on Topics, Including:
DIFS’ Appeals vs. Civil Lawsuits:
Pros/Cons & How to Choose Your Best Path
“Judicial Review” of DIFS’ Decision(s)
Responding to Insurer/MCCA Requests
Grounds for Insurer/MCCA Denials of Provider Bills
“Medically Accepted Standards” for Denial
Official Disability Guidelines (“ODG”)
Breakout Discussions and Q&A for:
Provider Group I: Provider Group II: Provider Group III: General Q&A Concluding Remarks